In prostate cancer, which typically forms osteoblastic lesions characterized by high bone formation, the levels of sclerostin, or DKK-1, can vary during disease progression [109], adding complexity to our understanding of the role of osteocytes in this process. This evidence concerns the gene DKK1 and Familial prostate cancer.